Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Preclinical studies have demonstrated that nerve growth factor may prevent or reverse peripheral neuropathy. We have therefore tested the effects of recombinant human nerve growth factor in patients with diabetic polyneuropathy. METHODS: A total of 250 patients with symptomatic diabetic polyneuropathy randomly received either placebo or one of two doses of recombinant human nerve growth factor for 6 months. Patients were assessed for symptoms and signs of polyneuropathy before and after treatment. RESULTS: Compared with placebo, recombinant human nerve growth factor led to significant improvement after 6 months of treatment, as measured by the sensory component of the neurologic examination, two quantitative sensory tests, and the impression of most subjects that their neuropathy had improved. Three prospectively identified multiple endpoint analyses indicated improvements in the nerve growth factor treatment groups over the placebo group in all three analyses (p = 0.032; p = 0.008; p = 0.005). Recombinant human nerve growth factor was well tolerated, with injection site discomfort reported as the most frequent adverse event. CONCLUSIONS: Recombinant human nerve growth factor appears to be safe and shows preliminary evidence of efficacy in patients with symptomatic diabetic polyneuropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autosomal dominant cerebellar phenotypes: The genotype has settled the issue
Rosenberg, R. N. (1995) · Neurology · doi:10.1212/wnl.45.1.1 · Cited by 402
Hellweg, R., & Hartung, H. ‐. (1990) · Journal of Neuroscience Research · doi:10.1002/jnr.490260217 · Cited by 315
Nerve growth factor administration protects against experimental diabetic sensory neuropathy
Apfel, S. C., Arezzo, J. C., Brownlee, M., Federoff, H., & Kessler, J. A. (1994) · Brain Research · doi:10.1016/0006-8993(94)90252-6 · Cited by 285
Self-citationA 4, 2, and 1 stepping algorithm for quick and accurate estimation of cutaneous sensation threshold
Dyck, P. J., O'Brien, P. C., Kosanke, J. L., Gillen, D. A., & Karnes, J. L. (1993) · Neurology · doi:10.1212/wnl.43.8.1508 · Cited by 275
Treatment of Severe Chloroquine Poisoning
Riou, B., Barriot, P., Rimailho, A., & Baud, F. J. (1988) · New England Journal of Medicine · doi:10.1056/nejm198801073180101 · Cited by 266
Day, N. E., & Walter, S. D. (1984) · Biometrics · doi:10.2307/2530739 · Cited by 263
Nerve growth factor prevents toxic neuropathy in mice
Apfel, S. C., Lipton, R. B., Arezzo, J. C., & Kessler, J. A. (1991) · Annals of Neurology · doi:10.1002/ana.410290115 · Cited by 241
Self-citationAssessment [RETIRED]: Magnetoencephalography (MEG)
(1992) · Neurology · doi:10.1212/wnl.42.1.1 · Cited by 232
Rogers, R. L., Meyer, J. S., Mortel, K. F., Mahurin, R. K., & Judd, B. W. (1986) · Neurology · doi:10.1212/wnl.36.1.1 · Cited by 218
Nerve growth factor prevents experimental cisplatin neuropathy
Apfel, S. C., Arezzo, J. C., Lipson, L., & Kessler, J. A. (1992) · Annals of Neurology · doi:10.1002/ana.410310114 · Cited by 210
Self-citationDyck, P. J., Bushek, W., Spring, E. M., Karnes, J. L., Litchy, W. J., O'Brien, P. C., & Service, F. J. (1987) · Diabetes Care · doi:10.2337/diacare.10.4.432 · Cited by 179
Self-citationHellweg, R., Raivich, G., Hartung, H.-D., Höck, C., & Kreutzberg, G. W. (1994) · Experimental Neurology · doi:10.1006/exnr.1994.1181 · Cited by 155
Bogardus, C., Taskinen, M.-R., Zawadzki, J., Lillioja, S., Mott, D., & Howard, B. V. (1986) · Diabetes · doi:10.2337/diab.35.1.1 · Cited by 99
Granata, A., & Kitai, S. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-01-00001.1992 · Cited by 74
Dementia: A Brief and Selective Review
Terry, R. D. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500010003001 · Cited by 74
Excitotoxic neuronal cell death in amyotrophic lateral sclerosis
Appel, S. H. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90039-o · Cited by 73
Inhibition of axonal growth from sensory neurons by excess nerve growth factor
Conti, A. M. F., Fischer, S. J., & Windebank, A. J. (1997) · Annals of Neurology · doi:10.1002/ana.410420604 · Cited by 70
MacLean, D. B., Bennett, B. A., Morris, M., & Wheeler, F. B. (1989) · Brain Research · doi:10.1016/0006-8993(89)91515-1 · Cited by 47
Policies on reporting clinical trials and publishing supplements
Kieburtz, K. D. (1997) · Neurology · doi:10.1212/wnl.49.1.2 · Cited by 30
Picrotoxin and pentylene tetrazole induced seizure activity in pyridoxine-deficient rats
Sharma, S. K., Bolster, R. B., & Dakshinamurti, K. (1994) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)90148-1 · Cited by 25
Axonal regeneration of identified septohippocampal projection neuronsin vitro
Linke, R., Heimrich, B., & Frotscher, M. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00174-h · Cited by 21
(1993) · Journal of Neuroscience · doi:10.1523/jneurosci.13-12-j0001.1993 · Cited by 4
Cited by
Boulton, A. J. M., Malik, R. A., Arezzo, J. C., & Sosenko, J. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1458 · Cited by 913
Potential therapeutic uses of BDNF in neurological and psychiatric disorders
Nagahara, A. H., & Tuszynski, M. H. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3366 · Cited by 867
Diabetic neuropathy: cellular mechanisms as therapeutic targets
Vincent, A. M., Callaghan, B. C., Smith, A. L., & Feldman, E. L. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.137 · Cited by 566
Neurological complications of HIV infection
McArthur, J. C., Brew, B. J., & Nath, A. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70165-4 · Cited by 554
Neurotrophic factors in Alzheimer’s and Parkinson’s disease brain
Siegel, G. J., & Chauhan, N. B. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00030-8 · Cited by 496
Metadata
- Authors
- Apfel, S. C., Kessler, J. A., Adornato, B. T., Litchy, W. J., Sanders, C., Rask, C. A., & The NGF Study Group*
- Venue
- Neurology
- Published
- 1998-09
- Volume
- 51
- Issue
- 3
- Pages
- 695-702
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2976216518
- Cited by
- 289
- References
- 22
- FWCI
- 14.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.